Patents by Inventor Michelle Georgiou
Michelle Georgiou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230414699Abstract: Provided is a pharmaceutical composition which comprises a nucleophilic compound capable of inhibiting carbamylation, for use in the treatment of a condition involving cutaneous or connective tissue damage. A method for treating a condition involving cutaneous or connective tissue damage in a patient, is also provided, said method comprising administering a said pharmaceutical composition to said patient.Type: ApplicationFiled: October 8, 2021Publication date: December 28, 2023Applicant: MC2 Therapeutics LtdInventors: Torkil Menne, Johan Selmer, Jesper Lange, Jon Bondebjerg, Michelle Georgiou
-
Patent number: 11744799Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.Type: GrantFiled: January 30, 2018Date of Patent: September 5, 2023Assignee: MC2 Therapeutics LimitedInventors: Nigel Crutchley, Michelle Georgiou
-
Publication number: 20230226077Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.Type: ApplicationFiled: March 20, 2023Publication date: July 20, 2023Applicant: MC2 Therapeutics LimitedInventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
-
Patent number: 11696919Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.Type: GrantFiled: March 18, 2019Date of Patent: July 11, 2023Assignee: MC2 Therapeutics LimitedInventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
-
Patent number: 11638711Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.Type: GrantFiled: March 18, 2019Date of Patent: May 2, 2023Assignee: MC2 Therapeutics LimitedInventors: Nigel Crutchley, Michelle Georgiou, Stephen Lenon, Morten Praestegaard
-
Publication number: 20220110868Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises a continuous phase, a discontinuous phase and crisaborole.Type: ApplicationFiled: January 30, 2018Publication date: April 14, 2022Inventors: Nigel CRUTCHLEY, Michelle GEORGIOU
-
Patent number: 11065195Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: GrantFiled: February 27, 2019Date of Patent: July 20, 2021Assignee: MC2 Therapeutics LimitedInventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20210015831Abstract: The present invention relates to a composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase, wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and wherein the composition has a pH of 7.75±0.5.Type: ApplicationFiled: March 18, 2019Publication date: January 21, 2021Applicant: MC2 Therapeutics LimitedInventors: Nigel Crutchley, Michelle Georgiou, Stephen LENON, Morten PRAESTEGAARD
-
Publication number: 20210000796Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypetides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: ApplicationFiled: September 18, 2020Publication date: January 7, 2021Applicant: DRUG DELIVERY SOLUTIONS APSInventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
-
Patent number: 10806721Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: GrantFiled: June 16, 2017Date of Patent: October 20, 2020Assignee: DRUG DELIVERY SOLUTIONS APSInventors: Torkil Menne, Johan Selmer, Jesper Lange, Michelle Georgiou, Derek Wheeler, David Evans
-
Publication number: 20190358151Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: February 27, 2019Publication date: November 28, 2019Applicant: DRUG DELIVERY SOLUTIONS LIMITEDInventors: Derek WHEELER, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20190321336Abstract: There is provided a topical formulation comprising a nucleophile, such as amino acids and most polypeptides and/or a derivative thereof, for use in the treatment or prevention of itchy dry skin caused by urea, such as in uremic pruritus, of a subject. The amino acid may be histidine and the derivative may be a histidine degradation product, a peptide of histidine, a peptide of histidine and one or more additional amino acids, and a pharmaceutically-acceptable salt of histidine.Type: ApplicationFiled: June 16, 2017Publication date: October 24, 2019Inventors: Torkil MENNE, Johan SELMER, Jesper LANGE, Michelle GEORGIOU, Derek WHEELER, David EVANS
-
Patent number: 10265265Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analog and at least one corticosteroid.Type: GrantFiled: March 14, 2008Date of Patent: April 23, 2019Assignee: DRUG DELIVERY SOLUTIONS LIMITEDInventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20080234239Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: March 14, 2008Publication date: September 25, 2008Inventors: Derek Wheeler, David F. Steele, Michelle Georgiou, Steen Sindet-Pedersen
-
Publication number: 20080227759Abstract: A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.Type: ApplicationFiled: September 27, 2007Publication date: September 18, 2008Inventors: Derek Wheeler, Steen Sindet-Pedersen, David F. Steele, Michelle Georgiou
-
Publication number: 20060228408Abstract: An oral drug delivery system which comprises a biliquid foam comprising: from 1 to 20% by weight of a continuous hydrophilic phase, from 70 to 98% by weight of a pharmaceutically acceptable oil which forms a discontinuous phase, the said pharmaceutically acceptable oil having dissolved or dispersed therein a poorly water-soluble drug in an amount of from 0.1 to 20% by weight and the biliquid foam including therein from 0.5 to 10% by weight of a surfactant to enable the formation of a stable biliquid foam, all percentages being based upon the total weight of the formulation.Type: ApplicationFiled: July 30, 2004Publication date: October 12, 2006Inventors: William Charman, Monica Dias, Michelle Georgiou, Philip Guffogg, Christopher Porter, Colin Pouton, Fraser Steele, Derek Wheeler